206 related articles for article (PubMed ID: 31488082)
1. Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes.
McQuerry JA; Jenkins DF; Yost SE; Zhang Y; Schmolze D; Johnson WE; Yuan Y; Bild AH
BMC Cancer; 2019 Sep; 19(1):881. PubMed ID: 31488082
[TBL] [Abstract][Full Text] [Related]
2. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
Basho RK; Yam C; Gilcrease M; Murthy RK; Helgason T; Karp DD; Meric-Bernstam F; Hess KR; Valero V; Albarracin C; Litton JK; Chavez-MacGregor M; Hong D; Kurzrock R; Hortobagyi GN; Janku F; Moulder SL
Oncologist; 2018 Nov; 23(11):1300-1309. PubMed ID: 30139837
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma.
Krings G; Chen YY
Mod Pathol; 2018 Nov; 31(11):1661-1674. PubMed ID: 29946183
[TBL] [Abstract][Full Text] [Related]
5. Compartmental Syndecan-1 (CD138) expression as a novel prognostic marker in triple-negative metaplastic breast cancer.
Ismail Y; Zakaria AS; Allam R; Götte M; Ibrahim SA; Hassan H
Pathol Res Pract; 2024 Jan; 253():154994. PubMed ID: 38071886
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological characteristics of metaplastic breast cancer - analysis of the basic immunohistochemical profile and comparison with other invasive breast cancer types.
Budzik MP; Patera J; Sobol M; Czerw AI; Deptała A; Badowska-Kozakiewicz AM
Breast; 2019 Feb; 43():135-141. PubMed ID: 30553188
[TBL] [Abstract][Full Text] [Related]
7. The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer.
Hu J; Lang R; Zhao W; Jia Y; Tong Z; Shi Y
Breast Cancer Res Treat; 2023 Jul; 200(1):23-36. PubMed ID: 37160814
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations.
Reddy TP; Rosato RR; Li X; Moulder S; Piwnica-Worms H; Chang JC
Breast Cancer Res; 2020 Nov; 22(1):121. PubMed ID: 33148288
[TBL] [Abstract][Full Text] [Related]
9. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
10. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
[TBL] [Abstract][Full Text] [Related]
11. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological features of metaplastic breast carcinoma.
Hasdemir OA; Tokgöz S; Köybaşıoğlu F; Karabacak H; Yücesoy C; İmamoğlu Gİ
Adv Clin Exp Med; 2018 Apr; 27(4):509-513. PubMed ID: 29558027
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of a Glycolytic Signature and Its Regulation by Y-Box-Binding Protein 1 in Triple-Negative Breast Cancer.
Lai YW; Hsu WJ; Lee WY; Chen CH; Tsai YH; Dai JZ; Yang CC; Lin CW
Cells; 2021 Jul; 10(8):. PubMed ID: 34440660
[TBL] [Abstract][Full Text] [Related]
14. Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer.
Koleckova M; Ehrmann J; Bouchal J; Janikova M; Brisudova A; Srovnal J; Staffova K; Svoboda M; Slaby O; Radova L; Vomackova K; Melichar B; Veverkova L; Kolar Z
Sci Rep; 2021 Mar; 11(1):5145. PubMed ID: 33664322
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma
Shan NL; Minden A; Furmanski P; Bak MJ; Cai L; Wernyj R; Sargsyan D; Cheng D; Wu R; Kuo HD; Li SN; Fang M; Maehr H; Kong AN; Suh N
Cancer Prev Res (Phila); 2020 Aug; 13(8):673-686. PubMed ID: 32467291
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Metaplastic Breast Cancer Versus Triple-Negative Breast Cancer: A Propensity Score Matching Analysis.
Tan Y; Yang B; Chen Y; Yan X
World J Surg; 2023 Dec; 47(12):3192-3202. PubMed ID: 37709983
[TBL] [Abstract][Full Text] [Related]
17. Myeloid Zinc Finger 1 (MZF1) Maintains the Mesenchymal Phenotype by Down-regulating IGF1R/p38 MAPK/ERα Signaling Pathway in High-level MZF1-expressing TNBC cells.
Yue CH; Liu JY; Chi CS; Hu CW; Tan KT; Huang FM; Pan YR; Lin KI; Lee CJ
Anticancer Res; 2019 Aug; 39(8):4149-4164. PubMed ID: 31366500
[TBL] [Abstract][Full Text] [Related]
18. Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma.
Lien HC; Hsu CL; Lu YS; Chen TW; Chen IC; Li YC; Huang CS; Cheng AL; Lin CH
Breast Cancer Res; 2023 Jan; 25(1):11. PubMed ID: 36707876
[TBL] [Abstract][Full Text] [Related]
19. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.
Yam C; Abuhadra N; Sun R; Adrada BE; Ding QQ; White JB; Ravenberg EE; Clayborn AR; Valero V; Tripathy D; Damodaran S; Arun BK; Litton JK; Ueno NT; Murthy RK; Lim B; Baez L; Li X; Buzdar AU; Hortobagyi GN; Thompson AM; Mittendorf EA; Rauch GM; Candelaria RP; Huo L; Moulder SL; Chang JT
Clin Cancer Res; 2022 Jul; 28(13):2878-2889. PubMed ID: 35507014
[TBL] [Abstract][Full Text] [Related]
20. Metaplastic carcinoma show different expression pattern of YAP compared to triple-negative breast cancer.
Min Kim H; Kim SK; Jung WH; Koo JS
Tumour Biol; 2015 Feb; 36(2):1207-12. PubMed ID: 25344213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
